Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT02925494 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02925494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02925494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2016
Completion date
March 22, 2019
Enrollment
433 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

heavy menstrual bleeding, uterine fibroids